Alkermes Reports $30.1M Q1 EBITDA Loss, Signaling Continued Financial Headwinds
Summary
Alkermes plc reported a first-quarter EBITDA loss of $30.1 million. This specific Q1 financial result provides an early indication of the company's performance, following its last 10-K filing in February which projected a GAAP net loss for the full fiscal year 2026. While a loss was anticipated, the magnitude of the Q1 EBITDA loss will be a key data point for investors assessing the company's progress and its ability to manage costs and generate revenue from its product pipeline and recent acquisition. Traders will be watching for further details on revenue performance and any updates to full-year guidance.
At the time of this announcement, ALKS was trading at $34.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7B. The 52-week trading range was $25.17 to $36.48. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.